Page 27 - GTM-4-3

Global Translational Medicine Anti-inflammatory therapy in CVD

remodeling. Although GDF-15’s role in metabolic Further disclosure
45
regulation has made it a target in obesity and diabetes, its
application in CVD remains an area of active investigation. Part I of this review can be accessed at doi:10.36922/
GTM025100023
10. Conclusion References
The therapeutic intervention of CVD has evolved, 1. Taylor F, Huffman MD, Macedo AF, et al. Statins for the
recognizing inflammation as a critical driver of disease primary prevention of cardiovascular disease. Cochrane
progression and treatment response. While statins remain Database Syst Rev. 2013;2013(1):CD004816.
central to lipid-lowering therapy, advances in gene-based
treatments, triglyceride-targeting agents, and novel anti- doi: 10.1002/14651858.CD004816.pub5
inflammatory strategies have expanded therapeutic 2. Kapur NK, Musunuru K. Clinical efficacy and safety of
options. Future research should prioritize optimizing statins in managing cardiovascular risk. Vasc Health Risk
combination therapies, refining patient selection, and Manag. 2008;4(2):341-353.
addressing residual inflammatory risk to improve doi: 10.2147/vhrm.s1653
cardiovascular outcomes.
3. Ridker PM, Danielson E, Fonseca FAH, et al. Rosuvastatin
Acknowledgments to prevent vascular events in men and women with elevated
C-reactive protein. N Engl J Med. 2008;359(21):2195-2207.
None.
doi: 10.1056/NEJMoa0807646
Funding 4. Luo Y, Hou Y, Zhao W, Yang B. Recent progress in gene
None. therapy for familial hypercholesterolemia treatment.
iScience. 2024;27(9):110641.
Conflict of interest doi: 10.1016/j.isci.2024.110641
Krishnaswami Vijayraghavan is the Guest Editor for this 5. Pontremoli R, Bellizzi V, Bianchi S, et al. Management
special issue but was not in any way involved in the editorial of dyslipidaemia in patients with chronic kidney disease:
and peer-review process conducted for this paper, directly A position paper endorsed by the Italian society of
or indirectly. While, Corina Grancorvitz is an employee nephrology. J Nephrol. 2020;33(3):417-430.
of Kiniksa Pharmaceuticals but declared no known doi: 10.1007/s40620-020-00707-2
competing financial interests or personal relationships
that could have influenced the work reported in this 6. Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe
added to statin therapy after acute coronary syndromes.
paper. Other authors declared that they have no known N Engl J Med. 2015;372(25):2387-2397.
competing financial interests or personal relationships that
could have influenced the work reported in this paper. doi: 10.1056/NEJMoa1410489
7. Robinson JG, Farnier M, Krempf M, et al. Efficacy and safety
Author contributions of alirocumab in reducing lipids and cardiovascular events.
Conceptualization: Krishnaswami Vijayraghavan, Tushar N Engl J Med. 2015;372(16):1489-1499.
Menon doi: 10.1056/NEJMoa1501031
Visualization: Tushar Menon, Vipan Chahil, Dhruv Patel, 8. Sabatine MS, Giugliano RP, Wiviott SD, et al. Efficacy and
Corina Grancorvitz safety of evolocumab in reducing lipids and cardiovascular
Writing – original draft: Tushar Menon, Vipan Chahil, events. N Engl J Med. 2015;372:1500-1509.
Dhruv Patel, Corina Grancorvitz
Writing – review & editing: Krishnaswami Vijayraghavan doi: 10.1056/NEJMoa1500858
9. Nissen SE, Lincoff AM, Brennan D, et al. Bempedoic acid
Ethics approval and consent to participate and cardiovascular outcomes in statin-intolerant patients.

Not applicable. N Engl J Med. 2023;388(15):1353-1364.
doi: 10.1056/NEJMoa2215024
Consent for publication
10. Ridker PM. Effects of Effects of bempedoic acid on CRP,
Not applicable. IL-6, fibrinogen and lipoprotein(a) in patients with residual
inflammatory risk: a secondary analysis of the CLEAR
Availability of data Harmony trial. J Clin Lipidol. 2023;17(3):297-304.
Not applicable. doi: 10.1016/j.jacl.2023.02.002

Volume 4 Issue 3 (2025) 19 doi: 10.36922/GTM025100024